UPCC 15820: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Enrolling By Invitation
99 years or below
All
1 Location
Brief description of study
The purpose of this study is to see if niraparib added to a standard treatment (abiraterone acetate and prednisone) will work better than abiraterone acetate and prednisone alone in treating men with metastatic prostate cancer with specific genetic changes. Eligible subjects will be men with metastatic prostate cancer.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 844249
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
